HSBC Holdings plc announced that details of changes to the composition of the Board and Committees following receipt of regulatory approval. Richard Henry Meddings (68) has been appointed as an independent non-executive Director of HSBC Holdings plc. He will also become a member of the Group Audit Committee, Group Risk Committee and Nomination & Corporate Governance Committee upon appointment. Mr. Meddings will succeed Brendan Nelson as Chair of the Group Audit Committee following the publication of the HSBC Interim Results on 4 August 2026, after a full handover of responsibilities to commence following his appointment to the Board. Eileen Murray has been appointed as Senior independent non-executive Director of HSBC Holdings plc, and independent non-executive Chair of HSBC Bank plc. Ms Murray will also step down as a member of the Group Risk Committee. Brendan Nelson will step down from his roles on the Group Technology and Operations Committee following the 2026 AGM, and will step down from the Group Audit and Group Risk Committees following the Interim Results. Mr. Nelson stood down from the HSBC UK board on 29 April 2026. The followings are details about Richard Henry Meddings. Date of Appointment: May 08, 2026. Service Address: 8 CANADA SQUARE LONDON UNITED KINGDOM E14 5HQ. Country/State Usually Resident: UNITED KINGDOM. Date of Birth: March, 1958. Nationality: BRITISH.
Committee Composition (taking effect from the conclusion of the Company's AGM on 8 May 2026). Group Audit Committee: Brendan Robert Nelson (Chair), Richard Henry Meddings, Geraldine Joyce Buckingham, Rachel Duan and James Anthony Forese. Group Risk Committee: James Anthony Forese (Chair), Wei Sun Christianson, Dame Carolyn Julie Fairbairn, Steven Craig Guggenheimer, Richard Henry Meddings, Brendan Robert Nelson and Swee Lian Teo. Group Remuneration Committee: Dame Carolyn Julie Fairbairn (Chair), Rachel Duan, Dr José Antonio Meade Kuribreña, Eileen K Murray and Kalpana Jaisingh Morparia. Group Technology and Operations Committee: Eileen K Murray (Chair), Steven Craig Guggenheimer, Kalpana Jaisingh Morparia and Swee Lian Teo. Nomination & Corporate Governance Committee: Brendan Robert Nelson (Chair), Geraldine Joyce Buckingham, Wei Sun Christianson, Rachel Duan, Dame Carolyn Julie Fairbairn, James Anthony Forese, Steven Craig Guggenheimer, Dr José Antonio Meade Kuribreña, Richard Henry Meddings, Kalpana Jaisingh Morparia, Eileen K Murray and Swee Lian Teo. Mr. Meddings served as Group Finance Director at Standard Chartered plc, where he had responsibility for Finance, Risk, Tax, Treasury, Strategy, Corporate Development and Investor Relations. Before joining Standard Chartered, he held the roles of Group Financial Controller and COO, Wealth Management at Barclays plc, following its acquisition of Woolwich plc (where he served as Group Finance Director). Mr. Meddings began his career at Price Waterhouse in 1980. Mr. Meddings is an experienced non-executive director and committee chair, and currently chairs the boards of Breast Cancer Now and Birmingham Health Partners. He previously served on the boards and as committee chair at: 3i Group plc (Chair of Audit & Risk Committee), Legal & General Group plc (Chair of Risk Committee), Deutsche Bank AG (Chair of Audit Committee), Jardine Lloyd Thompson Group plc (Chair of the Remuneration Committee), and Credit Suisse AG (Chair of the Audit Committee, and interim chair of the Risk Committee). Mr. Meddings also chaired NHS England between 2022 and 2025, and served on the board of HM Treasury between 2014 and 2021, where he chaired the Audit and Risk Committee. Other than disclosed above, Mr. Meddings has not held any directorships in any other publicly listed companies, whether in London, Hong Kong or overseas, during the previous five years. He does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company. Mr. Meddings appointment as a Director of the Company is subject to election by shareholders at the 2027 AGM and annual re-election thereafter. His initial three-year term will run from his initial election, if successful, until the 2030 AGM. As an Independent non-executive Director, Mr. Meddings will not have a service contract with the Company. Mr. Meddings does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance. Education and Professional Qualifications: Honorary Fellow, Exeter College Oxford (2023), Commander of the Order of the British Empire (2021) and Institute of Chartered Accountants of England and Wales (1983).